Clinical Trial Update: Study to Evaluate CORT125281 in Combination With Enzalutamide in Patients With mCRPC [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating CORT125281 in combination with enzalutamide in metastatic castration-resistant prostate cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• CORT125281
• Enzalutamide (enzalutamide)

Snippet

Sponsor: Corcept Therapeutics | Conditions: Metastatic Castration-Resistant Prostate Cancer | Phase 1, Phase 2 | Status: COMPLETED